After Q4 sales sink, Amgen CEO Bob Bradway details lofty growth strategy for 2030: Can he pull it off?

While Amgen boasted a 2% revenue boost last year, that growth was largely driven by profits from the company’s Covid-19 manufacturing deal with Eli Lilly, the company revealed in its Q4 results. To make up for declining Q4 sales, CEO Bob Bradway outlined a lofty growth strategy for the next…